An OpenData portal to share COVID-19 drug repurposing data in real time

The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign – named OpenData – with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover...

Descripción completa

Detalles Bibliográficos
Autores principales: Brimacombe, Kyle R., Zhao, Tongan, Eastman, Richard T., Hu, Xin, Wang, Ke, Backus, Mark, Baljinnyam, Bolormaa, Chen, Catherine Z., Chen, Lu, Eicher, Tara, Ferrer, Marc, Fu, Ying, Gorshkov, Kirill, Guo, Hui, Hanson, Quinlin M., Itkin, Zina, Kales, Stephen C., Klumpp-Thomas, Carleen, Lee, Emily M., Michael, Sam, Mierzwa, Tim, Patt, Andrew, Pradhan, Manisha, Renn, Alex, Shinn, Paul, Shrimp, Jonathan H., Viraktamath, Amit, Wilson, Kelli M., Xu, Miao, Zakharov, Alexey V., Zhu, Wei, Zheng, Wei, Simeonov, Anton, Mathé, Ewy A., Lo, Donald C., Hall, Matthew D., Shen, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276055/
https://www.ncbi.nlm.nih.gov/pubmed/32511420
http://dx.doi.org/10.1101/2020.06.04.135046
Descripción
Sumario:The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign – named OpenData – with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover a wide spectrum of the SARS-CoV-2 life cycle, including both viral and human (host) targets. In total, over 10,000 compounds are being tested in full concentration-response ranges from across multiple annotated small molecule libraries, including approved drug, repurposing candidates and experimental therapeutics designed to modulate a wide range of cellular targets. The goal is to support research scientists, clinical investigators and public health officials through open data sharing and analysis tools to expedite the development of SARS-CoV-2 interventions, and to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.

Ejemplares similares